| Literature DB >> 28031560 |
Anas Younes1, Stephen Ansell2, Nathan Fowler3, Wyndham Wilson4, Sven de Vos5, John Seymour6, Ranjana Advani7, Andres Forero8, Franck Morschhauser9, Marie Jose Kersten10, Kensei Tobinai11, Pier Luigi Zinzani12, Emanuele Zucca13, Jeremy Abramson14, Julie Vose15.
Abstract
The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens. In this Review, we describe the most-promising agents in clinical development for the treatment of lymphoma, and provide expert opinion on new strategies that might enable more streamlined drug development. We also address new approaches for patient selection and for incorporating new end points into clinical trials.Entities:
Mesh：
Substances：
Year: 2016 PMID： 28031560 PMCID： PMC5611863 DOI： 10.1038/nrclinonc.2016.205
Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675